 Nicholas Cost
Concepts (389)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 61 | 2025 | 352 | 17.060 |
Why?
| | Wilms Tumor | 33 | 2025 | 77 | 11.070 |
Why?
| | Testicular Neoplasms | 23 | 2023 | 101 | 9.530 |
Why?
| | Nephrectomy | 34 | 2025 | 163 | 6.670 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 14 | 2023 | 66 | 6.290 |
Why?
| | Lymph Node Excision | 13 | 2024 | 166 | 4.230 |
Why?
| | Carcinoma, Renal Cell | 17 | 2023 | 181 | 4.070 |
Why?
| | Rhabdoid Tumor | 5 | 2023 | 85 | 2.870 |
Why?
| | Lymph Nodes | 9 | 2023 | 458 | 2.740 |
Why?
| | Neoplasm Staging | 25 | 2023 | 1285 | 2.570 |
Why?
| | Urology | 8 | 2024 | 58 | 2.480 |
Why?
| | Urinary Bladder | 5 | 2024 | 175 | 2.290 |
Why?
| | Medical Oncology | 7 | 2023 | 273 | 2.280 |
Why?
| | Child | 91 | 2025 | 20824 | 2.190 |
Why?
| | Orchiectomy | 8 | 2023 | 64 | 2.080 |
Why?
| | Laparoscopy | 12 | 2024 | 452 | 2.060 |
Why?
| | Child, Preschool | 65 | 2025 | 10457 | 2.040 |
Why?
| | Rhabdomyosarcoma | 5 | 2022 | 63 | 1.920 |
Why?
| | Hydronephrosis | 6 | 2019 | 34 | 1.910 |
Why?
| | Adolescent | 67 | 2025 | 20197 | 1.810 |
Why?
| | Vincristine | 3 | 2024 | 109 | 1.790 |
Why?
| | Infant | 55 | 2025 | 8994 | 1.750 |
Why?
| | Lymphatic Metastasis | 12 | 2022 | 312 | 1.710 |
Why?
| | Urologic Surgical Procedures | 8 | 2019 | 106 | 1.680 |
Why?
| | Urologists | 3 | 2017 | 17 | 1.650 |
Why?
| | Urologic Neoplasms | 4 | 2017 | 25 | 1.580 |
Why?
| | Male | 102 | 2025 | 63146 | 1.510 |
Why?
| | Humans | 148 | 2025 | 128896 | 1.480 |
Why?
| | Kidney Pelvis | 6 | 2015 | 24 | 1.470 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 84 | 1.450 |
Why?
| | Robotics | 6 | 2015 | 88 | 1.450 |
Why?
| | Practice Patterns, Physicians' | 6 | 2024 | 1281 | 1.370 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 224 | 1.290 |
Why?
| | Lower Urinary Tract Symptoms | 2 | 2021 | 54 | 1.290 |
Why?
| | Organ Sparing Treatments | 4 | 2023 | 32 | 1.250 |
Why?
| | Pediatrics | 6 | 2024 | 1060 | 1.240 |
Why?
| | Doxorubicin | 2 | 2021 | 319 | 1.230 |
Why?
| | Kidney | 9 | 2023 | 1330 | 1.160 |
Why?
| | Ureteral Obstruction | 5 | 2015 | 59 | 1.160 |
Why?
| | Prognosis | 20 | 2025 | 3787 | 1.150 |
Why?
| | Urinary Bladder Diseases | 2 | 2019 | 18 | 1.140 |
Why?
| | Urodynamics | 3 | 2019 | 34 | 1.130 |
Why?
| | Retrospective Studies | 45 | 2025 | 14546 | 1.090 |
Why?
| | Female | 79 | 2025 | 68162 | 1.050 |
Why?
| | Tumor Burden | 6 | 2019 | 284 | 1.030 |
Why?
| | Young Adult | 32 | 2024 | 12286 | 0.970 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 22 | 0.960 |
Why?
| | Rhabdomyosarcoma, Embryonal | 2 | 2022 | 20 | 0.950 |
Why?
| | Nephrons | 9 | 2023 | 17 | 0.940 |
Why?
| | Urinary Tract | 2 | 2023 | 37 | 0.920 |
Why?
| | Biopsy | 6 | 2024 | 1093 | 0.900 |
Why?
| | Ribonuclease III | 3 | 2021 | 35 | 0.900 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 4 | 0.880 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 61 | 0.880 |
Why?
| | Sertoli-Leydig Cell Tumor | 3 | 2021 | 8 | 0.870 |
Why?
| | Hypospadias | 4 | 2011 | 28 | 0.840 |
Why?
| | Seminoma | 3 | 2021 | 17 | 0.840 |
Why?
| | Sarcoma, Clear Cell | 2 | 2023 | 8 | 0.830 |
Why?
| | Sarcoma | 3 | 2024 | 173 | 0.830 |
Why?
| | Urologic Surgical Procedures, Male | 4 | 2018 | 29 | 0.810 |
Why?
| | Spermatic Cord Torsion | 2 | 2013 | 3 | 0.800 |
Why?
| | Leydig Cell Tumor | 3 | 2021 | 7 | 0.800 |
Why?
| | Disease-Free Survival | 7 | 2022 | 657 | 0.780 |
Why?
| | Paraganglioma | 1 | 2022 | 49 | 0.760 |
Why?
| | Cryptorchidism | 2 | 2019 | 12 | 0.760 |
Why?
| | Age Factors | 12 | 2019 | 3133 | 0.740 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.730 |
Why?
| | Tomography, X-Ray Computed | 9 | 2021 | 2530 | 0.730 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 952 | 0.720 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 126 | 0.720 |
Why?
| | Pheochromocytoma | 2 | 2019 | 57 | 0.710 |
Why?
| | Infant, Newborn | 11 | 2023 | 5704 | 0.690 |
Why?
| | Surgeons | 3 | 2023 | 279 | 0.690 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 5 | 0.670 |
Why?
| | Neoplasms | 6 | 2024 | 2426 | 0.660 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 2 | 2017 | 5 | 0.650 |
Why?
| | Cystectomy | 1 | 2019 | 38 | 0.650 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 7 | 0.650 |
Why?
| | Muscle Relaxation | 1 | 2019 | 19 | 0.640 |
Why?
| | Neoplasm Invasiveness | 7 | 2017 | 479 | 0.640 |
Why?
| | Myosin Light Chains | 1 | 2019 | 27 | 0.640 |
Why?
| | Molecular Targeted Therapy | 2 | 2013 | 381 | 0.640 |
Why?
| | Treatment Outcome | 27 | 2025 | 10239 | 0.640 |
Why?
| | Retroperitoneal Space | 2 | 2024 | 16 | 0.630 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5355 | 0.620 |
Why?
| | Radiotherapy | 1 | 2019 | 186 | 0.620 |
Why?
| | Diagnostic Imaging | 3 | 2022 | 327 | 0.620 |
Why?
| | Fertility Preservation | 3 | 2024 | 54 | 0.620 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 120 | 0.610 |
Why?
| | Specimen Handling | 1 | 2019 | 163 | 0.610 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 52 | 0.610 |
Why?
| | Neoadjuvant Therapy | 4 | 2021 | 383 | 0.600 |
Why?
| | Catheterization | 1 | 2019 | 176 | 0.600 |
Why?
| | von Hippel-Lindau Disease | 1 | 2018 | 11 | 0.600 |
Why?
| | Testicular Diseases | 1 | 2018 | 6 | 0.600 |
Why?
| | Health Care Surveys | 2 | 2017 | 560 | 0.590 |
Why?
| | Calculi | 1 | 2018 | 16 | 0.580 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 508 | 0.570 |
Why?
| | Orchiopexy | 3 | 2019 | 5 | 0.570 |
Why?
| | Conservative Treatment | 1 | 2018 | 34 | 0.570 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 861 | 0.560 |
Why?
| | Radiation Exposure | 1 | 2017 | 48 | 0.560 |
Why?
| | Critical Pathways | 1 | 2018 | 80 | 0.560 |
Why?
| | Kidney Medulla | 1 | 2016 | 32 | 0.550 |
Why?
| | Cytodiagnosis | 1 | 2017 | 32 | 0.550 |
Why?
| | Frozen Sections | 1 | 2017 | 26 | 0.550 |
Why?
| | Risk Assessment | 10 | 2018 | 3286 | 0.540 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2353 | 0.540 |
Why?
| | Angiomyolipoma | 1 | 2016 | 18 | 0.540 |
Why?
| | Surgical Oncology | 1 | 2016 | 22 | 0.530 |
Why?
| | Cancer Survivors | 1 | 2021 | 260 | 0.530 |
Why?
| | Postoperative Care | 1 | 2018 | 246 | 0.530 |
Why?
| | Teratoma | 2 | 2017 | 101 | 0.530 |
Why?
| | Robotic Surgical Procedures | 2 | 2015 | 108 | 0.520 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 49 | 0.510 |
Why?
| | Muscle Contraction | 1 | 2019 | 426 | 0.510 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 13 | 0.510 |
Why?
| | Survival Rate | 9 | 2025 | 1884 | 0.490 |
Why?
| | Survival Analysis | 5 | 2019 | 1282 | 0.490 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 684 | 0.480 |
Why?
| | Adult | 23 | 2024 | 35361 | 0.480 |
Why?
| | Pediatricians | 1 | 2016 | 133 | 0.470 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1570 | 0.470 |
Why?
| | Adenoma | 1 | 2016 | 210 | 0.470 |
Why?
| | Neurofibromatosis 1 | 2 | 2019 | 44 | 0.470 |
Why?
| | Follow-Up Studies | 14 | 2025 | 4917 | 0.460 |
Why?
| | Pelvic Neoplasms | 2 | 2013 | 19 | 0.460 |
Why?
| | Cause of Death | 1 | 2016 | 392 | 0.460 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 2070 | 0.440 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 995 | 0.440 |
Why?
| | Ovarian Neoplasms | 3 | 2021 | 474 | 0.440 |
Why?
| | Hypertension | 1 | 2022 | 1236 | 0.430 |
Why?
| | Databases, Factual | 5 | 2019 | 1289 | 0.430 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2025 | 172 | 0.430 |
Why?
| | Ultrasonography | 5 | 2019 | 727 | 0.430 |
Why?
| | Acute-Phase Proteins | 1 | 2013 | 67 | 0.420 |
Why?
| | Lipocalins | 1 | 2013 | 36 | 0.420 |
Why?
| | Societies, Medical | 4 | 2018 | 760 | 0.420 |
Why?
| | SEER Program | 5 | 2019 | 208 | 0.420 |
Why?
| | Patient Education as Topic | 1 | 2018 | 734 | 0.410 |
Why?
| | Radiation Protection | 1 | 2013 | 37 | 0.410 |
Why?
| | Infertility | 2 | 2024 | 50 | 0.410 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2013 | 71 | 0.410 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 453 | 0.400 |
Why?
| | Biopsy, Needle | 1 | 2013 | 191 | 0.400 |
Why?
| | Multimodal Imaging | 1 | 2013 | 107 | 0.390 |
Why?
| | Glucose Transporter Type 1 | 1 | 2012 | 48 | 0.390 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 608 | 0.370 |
Why?
| | Incidence | 7 | 2019 | 2634 | 0.370 |
Why?
| | Primary Prevention | 1 | 2013 | 191 | 0.370 |
Why?
| | United States | 13 | 2024 | 13975 | 0.370 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 284 | 0.370 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1504 | 0.370 |
Why?
| | Codon | 1 | 2011 | 88 | 0.370 |
Why?
| | Proline | 1 | 2011 | 79 | 0.360 |
Why?
| | Combined Modality Therapy | 4 | 2023 | 1213 | 0.350 |
Why?
| | Vena Cava, Inferior | 1 | 2011 | 68 | 0.350 |
Why?
| | Seasons | 1 | 2013 | 502 | 0.350 |
Why?
| | Suburethral Slings | 1 | 2010 | 5 | 0.350 |
Why?
| | Prospective Studies | 9 | 2024 | 7060 | 0.350 |
Why?
| | Sex Factors | 3 | 2024 | 1947 | 0.340 |
Why?
| | Temperature | 1 | 2013 | 634 | 0.340 |
Why?
| | Hernia, Ventral | 1 | 2010 | 23 | 0.340 |
Why?
| | Arginine | 1 | 2011 | 254 | 0.340 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2010 | 34 | 0.330 |
Why?
| | Urinary Incontinence | 1 | 2010 | 62 | 0.330 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2112 | 0.330 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 636 | 0.330 |
Why?
| | Mouth Mucosa | 1 | 2009 | 89 | 0.320 |
Why?
| | Ureter | 4 | 2014 | 35 | 0.320 |
Why?
| | Campomelic Dysplasia | 1 | 2009 | 2 | 0.320 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 221 | 0.320 |
Why?
| | Dysgerminoma | 1 | 2009 | 6 | 0.320 |
Why?
| | Brachytherapy | 2 | 2021 | 103 | 0.320 |
Why?
| | Urethra | 2 | 2011 | 52 | 0.320 |
Why?
| | Recovery of Function | 1 | 2013 | 641 | 0.320 |
Why?
| | Venous Thrombosis | 1 | 2011 | 161 | 0.320 |
Why?
| | Skin Transplantation | 1 | 2009 | 87 | 0.320 |
Why?
| | Urolithiasis | 1 | 2009 | 9 | 0.320 |
Why?
| | Clitoris | 1 | 2009 | 9 | 0.310 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 1090 | 0.310 |
Why?
| | SOX9 Transcription Factor | 1 | 2009 | 25 | 0.310 |
Why?
| | Bone Neoplasms | 1 | 2011 | 227 | 0.310 |
Why?
| | Time Factors | 8 | 2019 | 6568 | 0.300 |
Why?
| | Surgical Flaps | 1 | 2009 | 140 | 0.300 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 786 | 0.290 |
Why?
| | Aged | 11 | 2021 | 22035 | 0.290 |
Why?
| | Health Promotion | 1 | 2013 | 712 | 0.270 |
Why?
| | Risk Factors | 8 | 2018 | 9792 | 0.270 |
Why?
| | Middle Aged | 12 | 2021 | 30977 | 0.260 |
Why?
| | Calcinosis | 1 | 2009 | 255 | 0.260 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1170 | 0.250 |
Why?
| | Ureterocele | 2 | 2016 | 7 | 0.250 |
Why?
| | Perioperative Care | 2 | 2024 | 150 | 0.250 |
Why?
| | Vesico-Ureteral Reflux | 2 | 2016 | 26 | 0.240 |
Why?
| | Kidney Diseases | 1 | 2009 | 366 | 0.240 |
Why?
| | Mitotic Index | 2 | 2015 | 26 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 870 | 0.240 |
Why?
| | Abdominal Neoplasms | 1 | 2024 | 32 | 0.230 |
Why?
| | Hypertrophy | 2 | 2019 | 120 | 0.230 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2013 | 380 | 0.230 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2024 | 62 | 0.210 |
Why?
| | Gonadal Dysgenesis | 1 | 2023 | 8 | 0.210 |
Why?
| | Adrenocortical Carcinoma | 1 | 2024 | 64 | 0.210 |
Why?
| | Mast Cells | 1 | 2024 | 142 | 0.210 |
Why?
| | Lymphocytes | 1 | 2025 | 369 | 0.210 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 189 | 0.210 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 140 | 0.200 |
Why?
| | Genetic Predisposition to Disease | 4 | 2024 | 2270 | 0.200 |
Why?
| | Pubic Bone | 1 | 2022 | 6 | 0.200 |
Why?
| | Monocytes | 1 | 2025 | 553 | 0.190 |
Why?
| | Algorithms | 1 | 2009 | 1626 | 0.190 |
Why?
| | Urination | 1 | 2022 | 44 | 0.190 |
Why?
| | Blood Platelets | 1 | 2025 | 369 | 0.190 |
Why?
| | Sertoli Cell Tumor | 1 | 2021 | 2 | 0.190 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2022 | 107 | 0.190 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 24 | 0.180 |
Why?
| | Aniridia | 1 | 2020 | 4 | 0.180 |
Why?
| | Testosterone | 2 | 2015 | 382 | 0.180 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2019 | 83 | 0.180 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1435 | 0.180 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 19 | 0.180 |
Why?
| | Reoperation | 3 | 2014 | 555 | 0.180 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 38 | 0.180 |
Why?
| | Pneumothorax | 1 | 2021 | 40 | 0.180 |
Why?
| | Codon, Nonsense | 1 | 2020 | 40 | 0.180 |
Why?
| | Interleukin-2 | 1 | 2022 | 427 | 0.180 |
Why?
| | Eye Proteins | 1 | 2020 | 84 | 0.170 |
Why?
| | Syndrome | 1 | 2021 | 342 | 0.170 |
Why?
| | Patient Selection | 3 | 2013 | 671 | 0.170 |
Why?
| | Priapism | 1 | 2019 | 9 | 0.170 |
Why?
| | Penile Neoplasms | 1 | 2019 | 7 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 1968 | 0.170 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 41 | 0.170 |
Why?
| | Proportional Hazards Models | 3 | 2011 | 1221 | 0.160 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 9 | 0.160 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 8 | 0.160 |
Why?
| | Neutrophils | 1 | 2025 | 1203 | 0.160 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 20 | 0.160 |
Why?
| | Length of Stay | 3 | 2024 | 1126 | 0.160 |
Why?
| | Computers | 1 | 2019 | 64 | 0.160 |
Why?
| | Puberty, Precocious | 1 | 2019 | 14 | 0.160 |
Why?
| | Postoperative Complications | 5 | 2024 | 2494 | 0.160 |
Why?
| | Decision Trees | 1 | 2019 | 90 | 0.160 |
Why?
| | Hospitals | 1 | 2023 | 628 | 0.160 |
Why?
| | Genotype | 2 | 2016 | 1834 | 0.160 |
Why?
| | Dermatofibrosarcoma | 1 | 2018 | 9 | 0.160 |
Why?
| | Genetic Testing | 2 | 2019 | 424 | 0.150 |
Why?
| | Diagnostic Errors | 1 | 2019 | 163 | 0.150 |
Why?
| | Aged, 80 and over | 4 | 2019 | 7050 | 0.150 |
Why?
| | Self-Examination | 1 | 2018 | 2 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 207 | 0.150 |
Why?
| | Proton Therapy | 1 | 2018 | 12 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 147 | 0.150 |
Why?
| | General Surgery | 1 | 2019 | 156 | 0.150 |
Why?
| | Mutation | 1 | 2009 | 3671 | 0.150 |
Why?
| | Preoperative Period | 1 | 2018 | 112 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 211 | 0.140 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 14 | 0.140 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 83 | 0.140 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.140 |
Why?
| | Analysis of Variance | 2 | 2017 | 1283 | 0.140 |
Why?
| | Testis | 1 | 2018 | 143 | 0.140 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 48 | 0.140 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 118 | 0.140 |
Why?
| | Animals | 5 | 2024 | 34628 | 0.140 |
Why?
| | Mice | 3 | 2024 | 16543 | 0.140 |
Why?
| | Intraoperative Period | 1 | 2017 | 53 | 0.140 |
Why?
| | Europe | 1 | 2018 | 366 | 0.140 |
Why?
| | Feasibility Studies | 2 | 2018 | 859 | 0.130 |
Why?
| | Logistic Models | 3 | 2018 | 1963 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 271 | 0.130 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 379 | 0.130 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1230 | 0.130 |
Why?
| | Certification | 1 | 2016 | 93 | 0.130 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.130 |
Why?
| | North America | 1 | 2016 | 289 | 0.130 |
Why?
| | Translocation, Genetic | 2 | 2018 | 97 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 2038 | 0.120 |
Why?
| | Models, Statistical | 1 | 2019 | 626 | 0.120 |
Why?
| | Learning | 1 | 2019 | 381 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1523 | 0.120 |
Why?
| | History, 21st Century | 1 | 2015 | 182 | 0.120 |
Why?
| | Phosphorylation | 1 | 2019 | 1685 | 0.120 |
Why?
| | Anaplasia | 2 | 2024 | 3 | 0.110 |
Why?
| | Registries | 2 | 2019 | 1916 | 0.110 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 44 | 0.110 |
Why?
| | Forecasting | 1 | 2016 | 363 | 0.110 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2014 | 19 | 0.110 |
Why?
| | Genitalia, Female | 1 | 2014 | 38 | 0.110 |
Why?
| | Inflammation | 1 | 2025 | 2694 | 0.110 |
Why?
| | Ureteral Calculi | 1 | 2014 | 13 | 0.110 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 68 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2014 | 149 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3348 | 0.110 |
Why?
| | Disease Management | 1 | 2017 | 594 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 424 | 0.100 |
Why?
| | Lipocalin-2 | 1 | 2013 | 76 | 0.100 |
Why?
| | Estrogens | 1 | 2015 | 348 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 896 | 0.100 |
Why?
| | Cohort Studies | 5 | 2016 | 5394 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 184 | 0.100 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 55 | 0.100 |
Why?
| | Spermatic Cord | 1 | 2012 | 1 | 0.100 |
Why?
| | Autophagy | 1 | 2014 | 263 | 0.100 |
Why?
| | Fetal Diseases | 1 | 2013 | 148 | 0.100 |
Why?
| | Creatinine | 1 | 2014 | 485 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 265 | 0.100 |
Why?
| | Radiation Dosage | 1 | 2013 | 159 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 210 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5032 | 0.090 |
Why?
| | Surgical Wound Dehiscence | 1 | 2011 | 22 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 828 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 60 | 0.090 |
Why?
| | Thrombectomy | 1 | 2011 | 58 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2016 | 727 | 0.090 |
Why?
| | Clinical Competence | 1 | 2017 | 1020 | 0.090 |
Why?
| | Texas | 1 | 2011 | 227 | 0.090 |
Why?
| | Bevacizumab | 1 | 2011 | 130 | 0.090 |
Why?
| | Compliance | 1 | 2010 | 50 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 494 | 0.090 |
Why?
| | Rectum | 1 | 2011 | 166 | 0.080 |
Why?
| | Pyrroles | 1 | 2011 | 201 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 513 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 1052 | 0.080 |
Why?
| | Operative Time | 3 | 2014 | 120 | 0.080 |
Why?
| | Muscle, Smooth | 1 | 2010 | 151 | 0.080 |
Why?
| | Penis | 2 | 2019 | 36 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1045 | 0.080 |
Why?
| | Pilot Projects | 1 | 2014 | 1545 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 760 | 0.080 |
Why?
| | Alleles | 1 | 2011 | 847 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 863 | 0.070 |
Why?
| | Remission, Spontaneous | 2 | 2021 | 38 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 668 | 0.070 |
Why?
| | Indoles | 1 | 2011 | 378 | 0.070 |
Why?
| | Congenital Abnormalities | 1 | 2008 | 74 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1967 | 0.070 |
Why?
| | Biomarkers | 2 | 2019 | 3874 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 548 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2014 | 3334 | 0.070 |
Why?
| | Pregnancy | 1 | 2018 | 6247 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2767 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 750 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 4857 | 0.060 |
Why?
| | Cystoscopy | 2 | 2016 | 18 | 0.060 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2024 | 13 | 0.060 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 37 | 0.060 |
Why?
| | Adrenalectomy | 1 | 2024 | 67 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1359 | 0.060 |
Why?
| | Nephroureterectomy | 1 | 2023 | 2 | 0.060 |
Why?
| | Neuroblastoma | 1 | 2024 | 152 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 19 | 0.050 |
Why?
| | Lymphoma | 1 | 2024 | 190 | 0.050 |
Why?
| | Gonads | 1 | 2023 | 23 | 0.050 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 914 | 0.050 |
Why?
| | Germany | 1 | 2020 | 99 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 81 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2024 | 637 | 0.040 |
Why?
| | Hyperplasia | 1 | 2019 | 171 | 0.040 |
Why?
| | Mohs Surgery | 1 | 2018 | 25 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 24 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2018 | 319 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 71 | 0.030 |
Why?
| | Ureteroscopy | 1 | 2016 | 16 | 0.030 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 44 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 436 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 15 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2014 | 20 | 0.030 |
Why?
| | Ureterostomy | 1 | 2014 | 3 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 254 | 0.030 |
Why?
| | Oncogenes | 1 | 2014 | 111 | 0.030 |
Why?
| | Cicatrix | 1 | 2014 | 56 | 0.030 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 446 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 680 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 448 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2014 | 673 | 0.020 |
Why?
| | Pain, Postoperative | 1 | 2013 | 227 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 32 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 285 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2011 | 277 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2706 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1840 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 180 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 343 | 0.020 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 2009 | 7 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1312 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3100 | 0.020 |
Why?
|
|
Cost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|